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ifferent Metabolic Effects of
elective and Nonselective
eta-Blockers Rather Than Mere
eart Rate Reduction May Be
he Mechanisms by Which
eta-Blockade Prevents
ardiovascular Events
e read with interest the article by Bangalore et al. (1), who
nalyzed in 9 trials the role of pharmacologic reduction of heart
ate (HR) using beta-blockers in preventing cardiovascular events
n patients with hypertension. Beta-blocker–induced lower HR
as associated with greater mortality and morbidity risk. As the
asis of worse outcomes with “beta-blockers,” the authors recog-
ize only an increase in central aortic/pulse pressure with pharma-
ologic HR lowering. Even though they acknowledge that the
eta-blocker used in the studies was mainly atenolol, and hence,
ny extrapolation of these results to other beta-blockers should be
one with caution, the whole paper and the accompanying
ditorial just generically refer to “beta-blockade.” In fact, the
echanisms by which beta-blockers improve prognosis in different
ardiac contexts are probably multiple. Improved energy efficiency
een with some beta-blockers (2) could be one of the reasons for
etter survival observed with their use (3). Additionally, central
nhibition of sympathetic activity with moxonidine in heart failure,
espite a significant reduction of HR, has been associated with
ncreased mortality (4). In fact, moxonidine has been shown to
lter myocardial metabolism (5). This could be the reason for the
ailure of central sympathetic inhibition to prevent deaths in
atients with heart failure and also indicates that the predominant
echanism of action of “effective” beta-blockers is probably related
o mechanisms other than mere HR reduction. In fact, apart from
educing HR, atenolol and most selective beta-blockers impair
ndothelial function, decrease insulin sensitivity, and increase lipid
evels (6), all conditions that may worsen the global risk profile.
onversely, new generation beta-blockers have been seen to
mprove metabolism and endothelial function (7). Therefore, HR
eduction in itself, especially if associated with a bulk of deleterious
etabolic and vascular effects, is definitely not enough to improve
rognosis. The alarm created by the Bangalore et al. (1) paper
hould be clearly confined to selective beta-blockers and not
enerically extended to the whole drug class.
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eta-Blockers and Hypertension
angalore et al. (1) state that unlike results from post-myocardial
nfarction and congestive heart failure studies, a beta-blocker–
nduced low heart rate (HR) in hypertension is associated with an
ncrease in death rate and cardiovascular (CV) events. This
onclusion is highly misleading.
In post-myocardial infarction and congestive heart failure studies,
he benefit from beta-1 blockade arises from decreased work of the
eart (via reduced HR and blood pressure), reduced ventricular
brillation risk, and a reduction in catecholamine-induced (beta-1)
ardiac necrosis and apoptosis (2); thus, intrinsic sympathomimetic
ctivity reduces efficacy (2). The situation with hypertension is
omplex, as diastolic hypertension in the young/middle-aged arises
rom a link with obesity (3) and high sympathetic nerve activity plus
aised cardiac output (2). In contrast, isolated systolic hypertension
rises in the elderly via a decrease in vascular compliance (3).
The 3 main contributor trials in the Bangalore et al. (1) study
ere the ASCOT (Anglo-Scandinavian Cardiac Outcomes),
IFE (Losartan Intervention for Endpoint Reduction in Hyper-
ension), and INVEST (International Verapamil SR Trandolapril
tudy) studies in elderly patients with hypertension, which in-
olved moderately beta-1 selective atenolol as the first-line choice.
tenolol does not improve vascular compliance (2), so it does not
ower central systolic pressure; indeed first-line atenolol slightly
ncreases central pressure (4), possibly linked to partial beta-2 block-
a
h
a
s
[
S
(
A
s
(
s
t
T
p
l
a
f
r
l
F
c
e
a
o
(
s
w
e
l
p
K
e
f
i
f
S
b
r
I
e
n
*
*
L
S
U
E
R
1
1
R
W
r
1
2
3
2106 Correspondence JACC Vol. 53, No. 22, 2009
June 2, 2009:2101–7de (2) and a fall in HR (1). Thus, a low HR would be linked to a
igh central pressure.
In contrast, second-line beta-blockade alongside a first-line
gent that improves vascular compliance and lowers central pres-
ures in the elderly (e.g., a low-dose diuretic or calcium antagonist
4]), is linked to highly significant falls in CV end points as in the
HEP (Systolic Hypertension in the Elderly Program), ALLHAT
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
ttack Trial), and MRC (Medical Research Council)-Elderly (2)
tudies.
The next 2 main contributor trials (1) were the IPPPSH
International Prospective Primary Prevention Study in Hyperten-
ion) and HAPPHY (Heart Attack Primary Prevention in Hyper-
ension) trials involving young/middle-aged hypertensive patients.
he first-line beta-blockers were nonselective oxprenolol and
artially beta-1 selective atenolol/metoprolol—beta-blockers that
ower blood pressure in different ways (5). Metoprolol and atenolol
ct via a fall in HR and cardiac output; oxprenolol acts via a modest
all in HR and cardiac output plus a modest fall in peripheral
esistance via beta-2 intrinsic sympathomimetic activity. Thus,
inking a final HR or HR difference with CV events is unhelpful.
or atenolol/metoprolol, quoting intra-trial (rather that end-trial)
hanges in HR (if known) would be useful, enabling HR/CV-
vent relationships to be studied.
Cigarette smoking is another relevant, vital issue for younger
nd middle-aged hypertensive patients, as significant benefit with
xprenolol (IPPPSH), propranolol (MRC-1), and metoprolol
MAPHY [Metoprolol Atherosclerosis Prevention in Hyperten-
ives]) occurred only in nonsmokers (2). Nonsmokers (70% of the
hole) in MRC-1 experienced a significant 38% reduction in CV
vents on propranolol, similar to the results of atenolol versus
ess-tight blood pressure control in overweight middle-aged hy-
ertensive patients with type-2 diabetes in the UKPDS (United
ingdom Prospective Diabetes Study) (6,7), in which all 7 hard
nd point trends (including myocardial infarction and stroke)
avoring the beta-blockers over the angiotensin-converting enzyme
nhibitor at 9-year follow-up (7), strengthened over 20-year
ollow-up, achieving significance in the case of all-cause death (8).
moking induces epinephrine release (9) and in the presence of
eta-1/beta-2 blockade, unopposed alpha stimulation occurs; the
esultant increase in blood pressure induces reflex falls in HR (10).
n such a scenario, a low HR would be linked to an increase in CV
vents. Such a worrisome beta-blocker-epinephrine interaction is
ot observed with high beta-1 selectivity (e.g., bisoprolol) (11).
John Malcolm Cruickshank, DM
42 Harefield
ong Melford
uffolk CO10 9DE
nited Kingdom
-mail: johndtl@aol.com
doi:10.1016/j.jacc.2008.11.066
EFERENCES
1. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker–
induced heart rate lowering and cardioprotection in hypertension.
J Am Coll Cardiol 2008;52:1482–9.2. Cruickshank JM. Are we misunderstanding beta-blockers? Int J Car-
diol 2007;120:10–27.3. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS.
Predictors of new-onset diastolic and systolic hypertension. The
Framingham Study. Circulation 2005;111:1121–7.
4. Morgan T, Lauri J, Bertram D, Anderson A. Effect of different anti-
hypertensive drug classes on central aortic pressure. Am J Hypertens
2004;17:118–23.
5. Man in’t Veld AJ, Schalekamp AD. Effects of 10 different beta-
adrenoceptor antagonists on hemodynamics, plasma rennin activity
and plasma norepinephrine in hypertension: the key role of vascular
resistance changes in relation to partial agonist activity. J Cardiovasc
Pharmacol 1983;5 Suppl 1:S30-45.
6. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type 2
diabetes: UKPDS 38. BMJ 1998;317:703-13.
7. Efficacy of atenolol and captopril in reducing risk of macrovascular and
microvascular complications in type 2 diabetes: UKPDS 39. BMJ
1998;317:713–20.
8. Holman RR, Paul SK, Bethel MA, Neil HA, Mathews DR. Long-
term follow-up after tight control of blood pressure in type-2 diabetes.
N Engl J Med 2008;359:1565–76.
9. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and
epinephrine release and adrenergic mediation of smoking-associated
haemodynamic and metabolic events. N Engl J Med 1976;295:573–7.
0. Lloyd-Mostyn RH, Oram S. Modification by propranolol of cardio-
vascular effects induced by hypoglycaemia. Lancet 1975;1:1213–5.
1. Tarnow J, Muller RK. Cardiovascular effect of low-dose epinephrine
infusions in relation to the extent of preoperative beta-adrenoceptor
blockade. Anaesthesiology 1991;74:1035–43.
eply
e thank the several authors who wrote a letter concerning our
ecent paper (1).
. Dr. Phillips’s criticism of our observation, being possibly the
result of confounding by indication, needs to be considered
carefully. Although we do not have definitive evidence to rule
this out, we think it is unlikely because in our data, there was
poor correlation between heart rate achieved at the end of
treatment and the systolic blood pressure difference between the
treatment modalities (r  0.154; p  0.717). Similarly, there
was no correlation between heart rate achieved and diastolic blood
pressure difference between treatment modalities (r  0.255;
p  0.542). This would indicate that the negative chronotropic
effect of beta-blockade can, to some extent, be dissociated from
its antihypertensive effect. However, as Dr. Phillips indicates,
the only way to rule out confounding by indication would be in
looking at the individual patient data, which obviously is no
longer possible.
. We agree with Drs. Aursnes and Osnes as well as with Dr.
Cockcroft that most of the findings in all meta-analyses of
beta-blocker trials are driven by atenolol. However, atenolol
remains the most widely prescribed beta-blocker worldwide,
with more than 40 million prescriptions per year in the U.S.
alone. No head-to-head comparisons of atenolol with other
beta-blockers have been done. Until we have convincing mor-
bidity and mortality data in trials done with beta-blockers other
than atenolol, we should not automatically exculpate these
agents. Thus, it is high time to sound the death knell for
atenolol, as Dr. Cockcroft suggests, but we should continue
prescribing beta-blockers (particularly those with a better he-
modynamic and metabolic profile) for well-defined cardiovas-
cular indications.
. We take issue with Dr. Gupta’s statement that our study merely
seeks “to convert a small-to-moderate statistical relative risk
into an absolute biological risk with important practical impli-
